| 52nd week of 2012 patent applcation highlights part 52 |
| Patent application number | Title | Published |
|---|
| 20120329712 | Induction of Differential Stress Resistance and Uses Thereof - This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents. | 2012-12-27 |
| 20120329713 | METHOD FOR DETERMINING LIKELIHOOD OF CLINICAL RECURRENCE OR CLINICALLY STABLE DISEASE OF PROSTATE CANCER AFTER RADICAL PROSTATECTOMY - This invention describes compositions and methods for use in PSA assays having low functional sensitivity which are useful, for example, in the detection of early stage recurrence of prostate disease following treatment and in the determination of whether patients have early stage biochemical reoccurrence (ES-BCR) or stable disease. | 2012-12-27 |
| 20120329714 | Prolactin Induced Increase in Neural Stem Cell Numbers - The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions. | 2012-12-27 |
| 20120329715 | GLP-1, EXENDIN-4, PEPTIDE ANALOGS AND USES THEREOF - The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects. | 2012-12-27 |
| 20120329716 | YELLOW PEA SEED PROTEIN-DERIVED PEPTIDES - The instant invention relates to peptides obtained from the enzymatic hydrolysis of yellow pea seed proteins that are capable of lowering the blood pressure and reducing the effects of kidney disease in a subject b\ inhibiting or reducing the affinity of the enzymes in the renin-angiotensin system for their substrates, specifically renin, to compositions comprising said peptides and to uses thereof. | 2012-12-27 |
| 20120329717 | NOVEL OMEGA CONOTOXIN PEPTIDES - This invention relates to an isolated, synthetic or recombinant peptide, wherein the peptide comprises the sequence: C K G K G A Xaa | 2012-12-27 |
| 20120329718 | COMPOSITIONS AND METHODS FOR TREATING ATRIAL FIBRILLATION - The present invention provides compositions and methods for treating heart conditions. In particular, the present invention provides compositions and methods that block G protein coupled receptor mediated signaling for treating atrial fibrillation. | 2012-12-27 |
| 20120329719 | Methods of use of skin wound healing compositions - A wound healing composition comprising a class of polypeptide compounds having a polypeptide chain with 5 to 120 amino acid units per chain. The composition includes a pharmaceutical medium to carry the polypeptide compound, such as an aqueous solution, suspension, dispersion, salve, ointment, gel, cream, lotion, spray or paste. Additionally, a method of applying a wound healing composition comprising a class of polypeptide compounds having a polypeptide chain with 5 to 120 amino acid units per chain in a concentration of from about 1 μg/ml to about 100 μg/ml for a time sufficient to heal the wound is disclosed. | 2012-12-27 |
| 20120329720 | ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF - The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-κB-dependent target gene expression in a cell. | 2012-12-27 |
| 20120329721 | MEANS FOR PREVENTING AND TREATING CELLULAR DEATH AND THEIR BIOLOGICAL APPLICATIONS - Inhibitors for preventing, blacking/silencing caspase-2 activity in cell death. | 2012-12-27 |
| 20120329722 | METHOD FOR ENZYMATICALLY PREPARING PEPTIDES FOR USE IN IMPROVEMENT OF BRAIN FUNCTION - The invention provides a method for preparing a peptide for improving brain function, comprising hydrolyzing milk casein with an enzymatic catalyst comprising a protease to produce a hydrolysate comprising: (i) a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a variant thereof; (ii) a peptide consisting of the amino acid sequence shown in SEQ ID NO: 2 or a variant thereof; or (iii) a mixture of the peptides of (i) and (ii), wherein the production yield of each of the peptides is 2% or more, or the total production yield of the mixture is 10% or more. The invention also provides a food or drink or a pharmaceutical composition containing the hydrolysate. | 2012-12-27 |
| 20120329723 | Biological Agents Active in Central Nervous System - Cell-permeant fusion peptides Tat-PDZ can dose-dependently reduce the threshold for anesthesia. PDZ domain-mediated protein interactions at synapses in the central nervous system play an important role in the molecular mechanisms of anesthesia. Moreover, Tat-PDZ cell-permeant fusion peptides are delivered intracellularly into neurons in the central nervous system subsequent to intraperitoneally injection. By in vitro and in vivo binding assays, we found that the Tat-PDZ dose-dependently inhibited the interactions between NMDARs and PSD-95. Furthermore, behavior testing showed that animals given Tat-PDZ exhibited significantly reduced established inflammatory pain behaviors compared to vehicle-treated group. Our results indicate that by disrupting NMDAR/PSD-95 protein interactions, the Tat-PDZ cell-permeable fusion peptides provide a new approach for inflammatory pain therapy. | 2012-12-27 |
| 20120329724 | PEPTIDE ANALOGUES - The present invention relates to compounds of Formula (I) | 2012-12-27 |
| 20120329725 | Chimeric Peptides for the Regulation of GTPases - Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer. The present invention generally relates to chimeric peptides capable of regulating GTPases, and more particularly, to methods of targeting individual GTPases by using GTPase-activating proteins. Such proteins may be used for the treatment of cancers and other GTPase-related diseases. This invention relates to nucleic acid molecules and the encoded GTPase activating proteins, and variants thereof, and to the use of these molecules in the characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly cancer. Disclosed herein are compounds and methods for regulating transcription of a selected gene. | 2012-12-27 |
| 20120329726 | Hair Shape Susceptibility Gene - A genetic polymorphism and a hair shape susceptibility gene that are related to hair shape, and a method for determining the genetic susceptibility to hair shape in individual test subjects are provided. Disclosed is a hair shape susceptibility gene, which overlaps with a haplotype block in 1q21.3 region (D1S2696 to D1S2346) of human chromosome 1 and comprises a portion or the entirety of the base sequence of the haplotype block, wherein the haplotype block is determined by a linkage disequilibrium analysis conducted on a single nucleotide polymorphism (SNP) marker whose allele frequency differs statistically significantly between a group having a curly hair trait and a group having a non-curly hair trait, and consists of a base sequence set forth in any one of SEQ ID NO: 1 to NO: 5. | 2012-12-27 |
| 20120329727 | TREATMENT OF UNCOUPLING PROTEIN 2 (UCP2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO UCP2 - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Uncoupling Protein 2 (UCP2), in particular, by targeting natural antisense polynucleotides of Uncoupling Protein 2 (UCP2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of UCP2. | 2012-12-27 |
| 20120329728 | COMPOSITIONS AND METHODS FOR MODULATING GAMMA-C-CYTOKINE ACTIVITY - The γc-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. The present embodiments relate to the design of peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. In several embodiments, peptide antagonists exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members. | 2012-12-27 |
| 20120329729 | Methods for treating diabetic foot ulcers - The present invention provides methods and pharmaceutical formulations for treating diabetic foot ulcers. | 2012-12-27 |
| 20120329730 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME - The disclosure provides aromatic-cationic peptide compositions and methods of preventing or treating disease using the same. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. | 2012-12-27 |
| 20120329731 | THERAPEUTIC METHODS, COMPOSITIONS, AND COMPOUNDS - In one embodiment the invention provides a method of combating cyanide poisoning, which comprises administering to a subject a compound capable of releasing 3-mercapto-pyruvate in vivo. In other embodiments the invention also provides pharmaceutical compositions comprising a compound capable of releasing 3-mercaptopyruvate in vivo, as well as novel compounds that are capable of releasing 3-mercaptopyruvate in vivo. | 2012-12-27 |
| 20120329732 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE - Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition. | 2012-12-27 |
| 20120329733 | METHODS AND PRODUCTS RELATED TO METABOLIC INTERACTIONS IN DISEASE - The invention involves methods of regulating cell growth and division to control disease processes by manipulating mitochondrial metabolism and the expression of cell surface immune proteins. The invention also involves related compositions and screening assays. | 2012-12-27 |
| 20120329734 | Mixture and infusion or drink solution - The invention relates to a mixture, wherein the mixture contains ribose, alanine and glycine. The mixture furthermore can contain glutamine and one or more of the following substances: valine, leucine, isoleucine, 5-hydroxy-tryptophan, tryptophan, cysteine, serine. Alternatively or in addition, the mixture furthermore can contain asparagine, arginine, proline and lysine. The invention furthermore relates to a mixture which contains ribose, glycine, proline, lysine, arginine and asparagine. | 2012-12-27 |
| 20120329735 | LIFESPAN EXTENDING AGENT - A lifespan extending agent that is safe for animals, and can easily be ingested in a form that resembles foods. A lifespan extending method is also disclosed. In the lifespan extending agent, a rare sugar usable as a sweetener is contained as an active ingredient. | 2012-12-27 |
| 20120329736 | Treatment for gastrointestinal disorders using a selective, site-activated binding system - The teachings provided herein generally relate to site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites. More particularly, the systems taught here include a phenolic compound bound to a reactive oxygen species, wherein the phenolic compound and the reactive oxygen species react at a target area in the presence of an oxidoreductase enzyme. | 2012-12-27 |
| 20120329737 | HYBRID MOLECULES MADE OF LIPIDS AND LIPID-ANALOGOUS COMPOUNDS AND USE THEREOF AS PHARMACEUTICAL OR COSMETIC PREPARATION - The invention relates to hybrid molecules made of two lipids or lipid-analogous compounds which are linked to each other via their lipophilic end. The hybrid molecules thereby have at least one hydrophilic group at their hydrophilic end for increasing the hydration shell of the hybrid molecule. The hybrid molecules according to the invention can be used as pharmaceutical or as a cosmetic preparation. | 2012-12-27 |
| 20120329738 | Water Soluble Drug-Solubilizer Powders and Their Uses - Enhanced methods have been discovered, using either sonication or homogenization followed by increased temperature and pressure, to solubilize compounds using diterpene glycosides and to produce a powder form of the compound-solubilizer complex than can be reconstituted in water. Without the diterpene glycoside, the compounds were insoluble or sparingly soluble in water, including some fat-insoluble vitamins. Water solutions of these compounds were made using a diterpene glycoside solubilizer, for example, rubusoside. The compound-solubilizer complex was then dehydrated to a stable powder that could then be reconstituted with water. A reconstituted drug-solubilizer complex (curcumin-rubusoside) was shown to be effective on reconstitution. In addition, the diterpene glycoside, rubusoside, was shown to be an inhibitor of permeability glycoprotein (P-gp), and will thus increase gastrointestinal absorption of certain drugs administered with rubusoside. | 2012-12-27 |
| 20120329739 | COMPOSITION FOR PREVENTING OR TREATING POLIOSIS OR VITILIGO COMPRISING A PUERARIA GENUS PLANT EXTRACT OR PUERARIN - Disclosed is a composition for preventing or treating poliosis or vitiligo comprising a | 2012-12-27 |
| 20120329740 | INSECTICIDAL N-SUBSTITUTED (6-HALOOALKYLPYRIDIN-3-YL)-ALKYL SULFOXIMINES - N-Substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines are effective at controlling insects. | 2012-12-27 |
| 20120329741 | NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF - Compounds of Formula I or II, and methods of making and using thereof, are described herein. | 2012-12-27 |
| 20120329742 | USE OF ANTIFUNGAL COMPOSITIONS TO TREAT UPPER GASTROINTESTINAL CONDITIONS - The present invention provides a novel method for treating oral conditions and upper gastrointestinal conditions in a subject by providing an inventive oral dosage form of a pharmaceutical composition comprising an effective amount of at least one antifungal and optionally a flavor modifier and/or salivation component such as an herbal component. In the present invention, the subjects have either not been diagnosed or do not have active or recurrent fungal infections. Specifically, the present invention is directed to chewable dosage forms. | 2012-12-27 |
| 20120329743 | CYCLOALKYL-FUSED TETRAHYDROQUINOLINES AS CRTH2 RECEPTOR MODULATORS - The invention provides certain cycloalkyl-fused tetrahydroquinolines of the Formula (I), | 2012-12-27 |
| 20120329744 | Doxorubicin Adjuvants to Reduce Toxicity and Methods for Using the Same - Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions. | 2012-12-27 |
| 20120329745 | PLANT DISEASE CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASE - The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more antibiotic fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease. group (A): a group consisting of kasugamycin, polyoxins, streptomycin, and validamycin | 2012-12-27 |
| 20120329746 | TRIAZOL COMPOUNDS FOR TREATING BIOFILM FORMATION - The present invention relates to the use of a Compound of formula I | 2012-12-27 |
| 20120329747 | NOVEL HYDRAZONE DERIVATIVES HAVING POTENT ANTITUMOR ACTIVITY TOWARD MULTI-DRUG RESISTANT TUMOR CELLS - A patentable new class of hydrazone derivative compounds is described, as are methods for synthesizing such compounds. The hydrazones of the invention can be used, for example, as potent anti-cancer agents, including to inhibit the growth of cancer cells that exhibit multidrug resistance. | 2012-12-27 |
| 20120329748 | ACTIVATION AND ACTIVATORS OF SIRT5 - The invention provides a method of increasing a deacetylase activity of SIRT5 by contacting SIRT5 with an agent that binds SIRT5 and reduces the K | 2012-12-27 |
| 20120329749 | Methods Of Preventing Or Treating Disease States Related To Certain Metabolic Abnormalities - The present invention relates to methods of treating, preventing, and/or improving disorders and conditions related to certain metabolic abnormalities including methods of improving blood lipid profiles and muscle recovery and repair in athletes, methods of treating fibromyalgia, erectile dysfunction, diseases associated with certain HLA-DQ gene alleles and/or gluten intolerance, including Celiac Disease, headaches and migraines, as well as idiopathic neuropathy, inability to sleep, inability to concentrate, and/or neurological development issues in children, the methods involving the administration of one or more downstream folate compounds and optionally methyl-B12. In one particular embodiment, the method comprises administration of L-methylfolate. In certain embodiments, the method further involves identifying a subject organism with a malfunction in one or more of the folate or B4 cycles. In certain embodiments, such a malfunction is one or more of the C677T and A1298C genetic polymorphisms. | 2012-12-27 |
| 20120329750 | METHOD FOR PRODUCING PURIFIED HEMATINIC IRON-SACCHARIDIC COMPLEX AND PRODUCT PRODUCED - A method for separating and purifying the active hematinic species (AHS) present in iron-saccharidic compositions, including AHS such as sodium ferric gluconate complex, ferric hydroxide-sucrose complex and ferric saccharate complex and others of similar form and function. The method separates the AHS from one or more excipients and, preferably, lyophilizes the separated AHS. Separation of the AHS permits its analytical quantification, further concentration, purification and/or lyophilization as well as preparation of new and useful products and pharmaceutical compositions, including those useful for the treatment of humans and animals. | 2012-12-27 |
| 20120329751 | METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS - Described herein are methods of disrupting (e.g., reducing the viscosity of, or dissolving) a preformed biofilm in a subject, the method comprising: administering to the subject an effective amount of a composition comprising a soluble chitosan or derivatized chitosan wherein the soluble chitosan or derivatized chitosan when administered contacts the preformed biofilm, thereby disrupting (e.g., reducing the viscosity of, or dissolving) the preformed biofilm. | 2012-12-27 |
| 20120329752 | ALLERGY INHIBITOR - The present invention provides an allergy inhibitor using the efficacy of amorphous paramylon which is a substance obtained by changing the crystalline structure of paramylon. | 2012-12-27 |
| 20120329753 | CHITOSAN-DERIVATIVE COMPOUNDS AND METHODS OF CONTROLLING MICROBIAL POPULATIONS - The present invention is directed to chitosan-derivative compounds and structures, methods of making chitosan-derivative compounds and methods for controlling, inhibiting and enhancing microbial populations in a variety of environments. The present invention is also directed to the control, inhibition and enhancement of microbial populations in animals, particularly humans. The microbial populations include bacteria, viruses and other pathogens where control of microbial populations are a necessity. The chitosan-derivative compounds of the present invention include chitosan-arginine compounds, related chitosan-L/D unnatural amino acid compounds, chitosan-acid amine compounds, chitosan-L/D natural amino acid derivative compounds, co-derivatives of the chitosan-derivative compounds, salts of the chitosan derivative compounds, and chitosan-guanidine compounds. | 2012-12-27 |
| 20120329754 | TOPICAL SKIN BARRIER - A topical skin barrier for protecting and promoting healing of skin, and for providing comfort to a patient, comprises a semi-solid hydrocarbon and a water-absorbing compound. The topical skin barrier effectively adheres to skin, affords protection from moisture and waste, and provides transparency in use. Methods of in vitro evaluation are for (i) a composition's protection from moisture and waste, and (ii) a composition's adhesion to skin. | 2012-12-27 |
| 20120329755 | GLYCOMIMETIC INHIBITORS OF THE PA-IL LECTIN, PA-IIL LECTIN OR BOTH THE LECTINS FROM PSEUDOMONAS - Compositions and methods are provided related to | 2012-12-27 |
| 20120329756 | FOOD COMPOSITION COMPRISING GLUCOSAMINE - The present invention relates to an orally ingestible food or pet food composition or cosmetic composition containing glucosamine generated from plant materials through a drying process for the maintenance of joint health or prevention, alleviation and/or treatment of osteoarthritis, or the improvement of the skin quality and prevention or restoration of age-related alterations of skin. It also relates to the use of the composition in the manufacture of a nutritional product, a supplement, a treat, a medicament or a cosmetic product and methods for the maintenance of bone health, prevention, alleviation and/or treatment of osteoarthritis, improvement of skin quality and prevention or restoration of age-related alterations of skin which comprises administering an effective amount of the composition. | 2012-12-27 |
| 20120329757 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis - Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided. | 2012-12-27 |
| 20120329758 | Combined Treatment Utilizing VB-201 - Methods of treatment which utilize co-administration of the oxidized lipid VB-201 with an additional therapeutically active agent are described herein. Methods of treating a cardiovascular disease are described herein, comprising co-administration of VB-201 and a statin to a subject who is not fully responsive to the statin, as well as methods of treating an inflammatory disease or disorder, comprising co-administration of VB-201 and glatiramer acetate. A pharmaceutical composition comprising VB-201, identified for use in combination with glatiramer acetate, is also described herein. Methods of determining a therapeutically effective amount of VB-201 in a subject and of determining a therapeutically effective amount of VB-201 for co-administration with an additional therapeutically active agent are also described. Novel unit dosage forms of VB-201 and methods utilizing same are also disclosed. | 2012-12-27 |
| 20120329759 | FORMULATIONS AND METHODS FOR VASCULAR PERMEABILITY-RELATED DISEASES OR CONDITIONS - Described herein are formulations and methods for treating, inhibiting, preventing, delaying onset, or causing regression of a disease or condition relating to vascular permeability. | 2012-12-27 |
| 20120329760 | RNASE 7 AS A MARKER FOR INFECTION - Methods of identifying a subject having a urinary tract infection using RNase 7 are described. The methods include providing a test sample of urine from the subject, determining the level of RNase 7 in the test sample, and then comparing the level of RNase 7 in the test sample to the level of RNase 7 in a control. A higher level of RNase 7 in the test sample indicates that the subject has an acute urinary tract infection, whereas a lower level of RNase 7 in the test sample indicates that the subject only has a chronic urinary tract infection. | 2012-12-27 |
| 20120329761 | USE OF TIGECYCLINE FOR TREATMENT OF CANCER - Cancer stem cells exhibit different metabolic profiles from other cancer cells, such that they do not readily respond to treatment using conventional chemotherapeutic agents. Studies disclosed herein now demonstrate that the glycylcycline antibiotic tigecycline (a tetracycline derivative) exhibits anti-cancer activity, including activity against cancer stem cells. This anti-neoplastic activity appears to be due to inhibition of mitochondrial protein synthesis in the cancer cells. In preferred embodiments, the cancer to be treated is a hematological cancer, such as leukemia, lymphoma or myeloma. | 2012-12-27 |
| 20120329762 | ANTI-THROMBOTIC COMPOUNDS - New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases. | 2012-12-27 |
| 20120329763 | ANTI-THROMBOTIC COMPOUNDS - New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases. | 2012-12-27 |
| 20120329764 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MIGRAINE HEADACHES - The present invention is related to compositions and methods for treating or reducing the likelihood of a migraine, reducing the severity of migraine, reducing the frequency of migraines, reducing the duration of migraine, and ameliorating the symptoms of a migraine. The methods and compositions of the present invention may also be used to treat or prevent condition characterized by increased cardiovascular risk or endothelial dysfunction and musculoskeletal symptoms. | 2012-12-27 |
| 20120329765 | MEDICINAL TARGETED LOCAL LIPOLYSIS - Aqueous phospholipid systems comprising at least one phospholipid, at least one bile acid and water are suitable for producing medicaments for the treatment of adipose tissue disorders and lead to regression of the pathologically proliferated adipose tissue. | 2012-12-27 |
| 20120329766 | FORMULATION - The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol, more particularly to a formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle. | 2012-12-27 |
| 20120329767 | Methods and Compositions for Treating Cancer - The present invention relates to uses or methods for treating proliferative diseases, in particular cancer, implementing ruthenium compounds, as well as to composition containing same. | 2012-12-27 |
| 20120329768 | PROCESS OF FORMING CRYSTALS FOR USE IN A PERSONAL CARE COMPOSITION - A method of making a stable detersive surfactant containing personal care composition comprising the steps of emulsifying a stabilizing agent in the presence of anionic surfactant to form an emulsion containing droplets having a particle size of from about 0.1 to about 10 um. These particles are then cooled to form a stabilizing premix at a rate of about 10 to about 1000 C/min to form crystals from the droplets, the crystals having a maximum dimension of about 0.1 to about 3 um. These crystals are then added to a detersive surfactant containing personal care composition to increase stability. | 2012-12-27 |
| 20120329769 | DIHYDROFURAN DERIVATIVES AS INSECTICIDAL COMPOUNDS - The present invention relates to compounds of formula (I) wherein Q is Q1 or Q2 P is P1, heterocyclylor heterocyclyl substituted by one to five Z; and wherein A | 2012-12-27 |
| 20120329770 | CEPHALOSPORIN DERIVATIVES USEFUL AS BETA-LACTAMASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to cephalosporin derivatives having β-lactamase inhibitory activity. The compounds are useful in preventing or treating bacterial resistance to an antibiotic, e.g. a β-lactam antibiotic. Disclosed herein are compounds that are inhibitors of class B metallo-β-lactamases, as well as class A, C, and D serine β-lactamases. In some preferred embodiments, the compounds are 3′-thiobenzoate derivatives of a cephalosporin. Pharmaceutical compositions, methods, uses, kits and commercial packages comprising the compounds are also disclosed. | 2012-12-27 |
| 20120329771 | BENZYLIC OXINDOLE PYRIMIDINES - The present invention encompasses compounds of general formula (I) | 2012-12-27 |
| 20120329772 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE - A compound having Formula (I) or Formula (II) | 2012-12-27 |
| 20120329773 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS - This invention relates to bicyclic ring system substituted amide functionalized phenols of general formula 1, | 2012-12-27 |
| 20120329774 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS - A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. | 2012-12-27 |
| 20120329775 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 - The present invention provides compounds of formula (I) | 2012-12-27 |
| 20120329776 | HETEROCYCLIC COMPOUNDS AND USES THEREOF - Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the isoquinolone entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein. | 2012-12-27 |
| 20120329777 | Amino-Heterocyclic Compounds - The invention provides PDE9-inhibiting compounds of Formula (I), | 2012-12-27 |
| 20120329778 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM - The present invention relates to bicyclic heterocycles of general formula | 2012-12-27 |
| 20120329779 | Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias - The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL. | 2012-12-27 |
| 20120329780 | Novel kinase inhibitors - The present invention relates to novel compounds of formula (I) | 2012-12-27 |
| 20120329781 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS - The instant invention relates to a combination, particularly a synergistic combination, of an alpha-2-delta ligand and a dual serotonin-noradrenaline re-uptake inhibitor (DSNRI) or one or both of a selective serotonin re-uptake inhibitor (SSRI) and a selective noradrenaline re-uptake inhibitor (SNRI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly neuropathic pain. | 2012-12-27 |
| 20120329782 | AZEPINE INHIBITORS OF JANUS KINASES - The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases. | 2012-12-27 |
| 20120329783 | COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF NICOTINE ACETYLCHOLINE RECEPTORS - The present invention concerns methods for treating or preventing neurological disorders characterized by dysfunction of nicotinic acetylcholine receptors by administering 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH), or a pharmaceutically acceptable salt thereof, to the patient. In another aspect, the present invention pertains to pharmaceutical compositions containing TMPH, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In another aspect, the present invention pertains to methods for selectively inhibiting nicotinic acetylcholine receptors that lack an α5, α6, or β3 subunit by contacting an effective amount of TMPH, or a pharmaceutically acceptable salt thereof, to the receptor. The method for selectively inhibiting nicotinic acethylcholine receptors that lack an α5 subunit can be carried out in vivo or in vitro. | 2012-12-27 |
| 20120329784 | COMPOUNDS AND METHODS - Disclosed are compounds having the formula: | 2012-12-27 |
| 20120329785 | Novel kinase inhibitors - The present invention relates to novel compounds of formula (I) | 2012-12-27 |
| 20120329786 | COMPOUNDS AND THERAPEUTIC USES THEREOF - The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders. | 2012-12-27 |
| 20120329787 | FUNGICIDAL PYRANONES AND OXAZINONES - Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, | 2012-12-27 |
| 20120329788 | METALLOENZYME INHIBITOR COMPOUNDS - The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes. | 2012-12-27 |
| 20120329789 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMERS DISEASE - Pharmaceutical compositions for treating Alzheimer's disease are disclosed. The pharmaceutical compositions include a compound having the general formula: | 2012-12-27 |
| 20120329790 | Dentinal Drug Delivery Composition - The present invention is a dentinal drug delivery composition composed of cationic and/or neutral porous particles containing an effective amount of a therapeutic agent and a method for using the same to provide a dental treatment. | 2012-12-27 |
| 20120329791 | Substituted Imidazopyridinyl-Aminopyridine Compounds - The present invention relates to substituted imidazopyridinyl-aminopyridine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted imidazopyridinyl-aminopyridine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof. | 2012-12-27 |
| 20120329792 | IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES - The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases. | 2012-12-27 |
| 20120329793 | Substituted Imidazopyridinyl Compounds - The present invention relates to substituted imidazopyridinyl compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted imidazopyridinyl compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof. | 2012-12-27 |
| 20120329794 | Ab1 KINASE INHIBITORS - The present invention provides an Abelson kinase (Abl kinase) inhibitor which comprises, as an active ingredient, an indazole derivative represented by Formula (I) (wherein R | 2012-12-27 |
| 20120329795 | QUINAZOLINE DERIVATIVES - The invention concerns quinazoline derivatives of Formula I: | 2012-12-27 |
| 20120329796 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA - The present invention relates to compound (I) wherein: means a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a halogen atom or a group chosen among a —CN group, a hydroxyl group, a —COOR | 2012-12-27 |
| 20120329797 | SECONDARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES FOR USE AS ANTIFUNGAL AGENTS - The present invention provides secondary 8-hydroxyquinoline-7-carboxamide derivatives of general formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful as antifungal agents. Specifically, these compounds were tested against | 2012-12-27 |
| 20120329798 | METHODS AND COMPOSITIONS FOR TREATING LUEKEMIA - A combination of a BCR-ABL inhibitor and a hedgehog pathway inhibitor for the treatment of leukemia. | 2012-12-27 |
| 20120329799 | PLANT DISEASE CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASE - The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more carboxamide fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease. Group (A): a group consisting of thifluzamide, oxadixyl, pencycuron, benalaxyl-M, fenhexamid, furametpyr, isopyrazam, isotianil, mepronil, tecloftalam, boscalid, fluopyram, fluopicolide, carpropamid, diclocymet, mandipropamid, dimethomorph, flumorph, penthiopyrad, and bixafen. | 2012-12-27 |
| 20120329800 | TREATMENT OF MUSCULAR DYSTROPHIES AND ASSOCIATED CONDITIONS BY ADMINISTRATION OF MONOAMINE OXIDASE INHIBITORS - Administration of a monoamine oxidase inhibitor is useful in the prevention and treatment of muscle dystrophy. Methods and compositions for inhibiting the production of reactive oxygen species in a muscle cell overproducing reactive oxygen species are provided herein. | 2012-12-27 |
| 20120329801 | CRYSTALLINE FORMS FOR 5-AMINO-2, 3-DIHYDROPHTHALAZINE-1, 4-DIONE SODIUM SALT, PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME AND METHOD FOR THE PRODUCTION OF SAID FORMS - The invention relates to the provision of two novel crystalline forms I and II for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt. Surprisingly, it was discovered that form I and form II have differing immunological effects. This advantageous property is useful for immunospecific applications. In addition, both forms have advantageous physicochemical properties, which are useful in the production, further processing and/or use of a pharmaceutical preparation of form I or form II or a mixture of both. | 2012-12-27 |
| 20120329802 | METALLOENZYME INHIBITOR COMPOUNDS - The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes. | 2012-12-27 |
| 20120329803 | Dihydropteridinones, method for production and use thereof - The present invention relates to new dihydropteridinones of general formula (12) wherein the groups R | 2012-12-27 |
| 20120329804 | Pyridopyrazindione Derivative and its Use as an Antiulcer Drug - The invention relates to the fields of the chemical and pharmaceutical industry and medicine and concerns a novel compound which can be used as an antiulcer agent. The compound is 9-(quinonyl-2)-2-p-ethoxyphenylethyl-4,5,6,7,8,9,10,11-octahydropyrido[1,2-a]pyrazindione-1,4 of formula (I), or pharmaceutically acceptable complex derivatives thereof. The compound can be used as an antiulcer agent. | 2012-12-27 |
| 20120329805 | PREPARATIONS AND METHODS FOR AMELIORATING OR REDUCING PRESBYOPIA - This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation. | 2012-12-27 |
| 20120329806 | NOVEL FLUOROERGOLINE ANALOGS - Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT | 2012-12-27 |
| 20120329807 | Multimeric VLA-4 Antagonists Comprising Polymers Moieties - Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis. | 2012-12-27 |
| 20120329808 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS - The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: | 2012-12-27 |
| 20120329809 | PURINE COMPOUNDS USED AS CB2 AGONISTS - A compound of the formula (I) and pharmaceutical compositions for the treatment of pain. | 2012-12-27 |
| 20120329810 | IMATINIB MESYLATE ORAL PHARMACEUTICAL COMPOSITION AND PROCESS FOR PREPARATION THEREOF - The invention relates to an oral pharmaceutical composition comprising, greater than 80% of Imatinib, by weight based on the total weight of the composition and the process for preparation thereof. | 2012-12-27 |
| 20120329811 | Heteroaromatic Derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors - The present invention relates to novel compounds of Formula (I), wherein X | 2012-12-27 |
